Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Oratecan |
Synonyms | |
Therapy Description |
Oratecan is a combination drug containing irinotecan and the P-glycoprotein (P-gp) efflux pump inhibitor HM30181AK, which may decrease efflux of irinotecan leading to increased intracellular accumulation, potentially leading to increased DNA damage and tumor cell death (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Oratecan | Irinotecan/P-glycoprotein Inhibitor HM30181AK | Oratecan is a combination drug containing irinotecan and the P-glycoprotein (P-gp) efflux pump inhibitor HM30181AK, which may decrease efflux of irinotecan leading to increased intracellular accumulation, potentially leading to increased DNA damage and tumor cell death (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02250157 | Phase I | Oratecan | A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies | Completed | USA | 0 |